Adaptive design is an innovative approach that allows to conduct clinical trials more efficiently (with fewer patients, in shorter terms) or to increase the likelihood of demonstrating the effect of the drug. In studies with adaptation, the possibility of modifying...
The aim of the new addendum is introducing improved and more effective approaches to design development, clinical trials, monitoring of their progress, documentation and reporting, and standards for the maintenance of electronic documentation and mandatory...
On August 18th, 2017, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase IV clinical study of the medicinal product Alflutop®. Protocol № OA-ALF-01 «An open-label multicenter randomized clinical...
Since March 27th to April 26th Skolkovo Biotechnology and Medical Cluster, Skolkovo Open University and fundamental medicine faculty hold the educational program “Pharma’s Cool 2017” . The program include innovative and technical experience...
On October, 30 IPHARMA received the Ministry of Health permission to conduct Phase I trial of Hondrolux®. Protocol № ОА-CLX-01 “Double-blind, randomized, placebo-controlled study to access safety and tolerability of single and following multiple...
5-7 февраля в Вене, Австрия, состоится ежегодная конференция DIA Europe 2019. В этом году на конференции ИФАРМА представит первую в России платформу по взаимодействию участников клинических исследований ClinLine.ru. По вопросам организации встреч и переговоров...
Компания Data MATRIX представила первый в России программный продукт, созданный на базе облачных технологий для сбора данных в клинических исследованиях. Уникальный для российского рынка продукт получил название MiniEDC. Новинка станет достойной альтернативой...
Moscow, Russia, January 2014. "TheraMAB" LLC. announces the beginning of multicenter Phase Ib/IIa clinical trial of multiple TAB08 i.v. administration. This is “first-in-class” anti-CD28 humanized mAb of IgG4 type for the treatment...
The Quality Assurance Forum began its work in June 2017. This Forum assembled quality assurance experts in pharmaceutical industry for the exchange of experience and mutual support. The first meeting of the Forum participants will be held on December 14...
On September, 28th, at 11:00 am, we will hold a webinar on the "Rules of granting subsidies to implement the projects on drug development under the "Pharma 2020" Federal Target Program”. Register to the webinar The webinar is devoted...
The webinar is dedicated to observation of the EEU Guideline "General considerations on clinical trials. EEU Guideline (based on ICH E8, ICH E1)". This guideline reveals general principles of the clinical study conduct, described in ICH E8, and provides...
On November, 9-10th, IPHARMA took part in VIIth Russian Congress of Patients . The problems of healthcare development, availability of drugs, quality of medical care and safety of patients have been discussed during the roundtable meetings and panel discussions...
On November, 16 th , at 11:00 am, we will hold a webinar on the “Highlights of the next-in-class drugs development”. The development of pharmacologically similar agents and improved analogues of innovative drugs (next-in-class) is one of the...
On November 14-15 the sixth international conference of the Adam Smith Institute "Clinical Research in Russia" will be held . IPHARMA is one of the sponsors of the conference. Under the program the latest regulatory changes, update the ICH GCP...
On May, 24th at 11:00 am, we will hold a webinar on the “Introduction to monitoring: the role of Clinical Research Associate, beginning, responsibilities” . Clinical Research Associate plays the key role in clinical trial. The quality and success...
On June 14 at 11:00 we will hold a webinar on the "Clinical trials in diabetes: approaches to drug development and methods for effectiveness and safety evaluating". Currently diabetology is one of the most actively developing branches of medical...
On January, 25th at 11:00 am, we will hold a webinar on the “Project management on start-up of clinical trial”. Register to webinar What will we discuss during the webinar? • The specifics of project management on start-up stage...
On February, 15th at 11:00 a.m., we will hold a webinar on the "Findings during the inspections of Federal Service for Surveillance in Healthcare (Roszdravnadzor) in 2016" . Register to the webinar What will we discuss during the webinar? ...
On April 15th at 11:00 a.m. , we will hold the webinar on “GCP for Drug developers (Sponsors). Quality Assurance system organization” . Poorly conducted clinical trials mean the lack of them. Quality and safety is the foundation of the pharmaceutical...
On April 19th at 11:00 a.m. , we will hold the webinar on “GCP for Investigators. Quality assurance system organization in investigator sites” . Organization of quality system is important for the Sponsors and for the investigator sites. Quality...
IPHARMA keeps leading positions among the contract research organizations in local clinical trials ( Research and information bulletin #14 Association of Clinical Trials Organization ACTO April, 6, 2017 ). In 2016 IPHARMA got 10 licences for conducting Phases...
On June 18-22nd IPHARMA will visit DIA 2017 Annual Meeting in Chicago, USA. IPHARMA will be presenting its business results for a third year running at the conference. We invite you to visit IPHARMA booth #847 to learn more of our company’s achievements...
We are pleased to invite you to DIA 2016 52st Annual Meeting, which takes place in Pennsylvania Convention Center, Philadelphia, PA, June 26-30, 2016. Our booth number is 644. Natalia Vostokova, IPHARMA Chief Operating Officer, will present a poster on the...
On November 8-10th, IPHARMA will take a part in the "Clinical trials in Russia" Adam Smith Forum which is the main event of the year in the clinical trials field. As in previous years, IPHARMA has become a sponsor of this event and will report...
On September 12, 2016, IPHARMA was authorized by the Ministry of Health of the Russian Federation to conduct the Phase IIa clinical trial of the medicinal product VM-1011. Protocol № HBV-VM1011-02 «A partially-blind randomized comparative pilot clinical...